Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.37 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | USP25 | Q9UHP3 | 4/20 | 0.34 |
| ▸ | USP28 | Q96RU2 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 3/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458971 | 0.86 | IP6K1 (0.38) | ADRB1IP6K1CNR2CNR1 | |
| SCHEMBL2461995 | 0.83 | ADRB1 (0.38) | ADRB1IP6K1USP25USP28 | |
| SCHEMBL2461911 | 0.78 | IP6K1 (0.36) | IP6K1CNR2CNR1 | |
| SCHEMBL2463505 | 0.78 | HDAC1 (0.39) | IP6K1CNR2CNR1PRKCQFLT3 | |
| SCHEMBL2463468 | 0.75 | CTSK (0.41) | IP6K1CNR2CNR1 | |
| SCHEMBL2461130 | 0.75 | IP6K1 (0.40) | IP6K1CNR2CNR1 | |
| SCHEMBL2461894 | 0.73 | HDAC1 (0.39) | CNR2CNR1 | |
| SCHEMBL2458839 | 0.73 | NR1H2 (0.41) | — | |
| SCHEMBL3452434 | 0.72 | IP6K1 (0.42) | IP6K1CNR2CNR1 | |
| SCHEMBL2461843 | 0.71 | NR1H2 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069315-B1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| US-7820649-B2 | Quinazolinone and isoquinolinone acetamide derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | NQO2, GATD3, SDHA | ADRB1 584/4885IP6K1 2048/4885CNR2 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.